Aquestive licenses Sympazan to Assertio for $9M upfront; up to $6M milestone

Aquestive Therapeutics, Inc.

Exclusive worldwide license of Sympazan (clobazam) oral film to Otter Pharmaceuticals (Assertio) for LGS.
Aquestive receives $9M upfront and will get $6M milestone upon patent allowance (notice already received Oct 27, 2022).
Aquestive will also receive royalties from Assertio and serve as exclusive manufacturer under long-term supply agreement.
Deal provides non-dilutive financing to focus on development of AQST-109 (epinephrine sublingual film) for anaphylaxis.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aquestive Therapeutics, Inc. entered into Assertio License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. valued at $9.0 million (effective 2022-10-26).

Action: entry
Agreement: license
Counterparty: Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc.
Value: $9.0 million
Effective: 2022-10-26

Exact text from the filing

Effective October 26, 2022, Aquestive Therapeutics, Inc. ("Aquestive" or the “Company”) entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio”), a specialty pharmaceutical company offering differentiated products to patients, to license Sympazan® (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox‐Gastaut syndrome (LGS) in patients aged two years of age or older (the "Assertio License Agreement").

View on SEC.gov

Browse all material agreements →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027190

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.